UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A prognostic scoring system based on clinical features of intrahepatic cholangiocarcinoma: the Fudan score

Annals of oncology, 2011-07, Vol.22 (7), p.1644-1652

2011

Volltextzugriff (PDF)

Randomized phase III trial of prophylactic cranial irradiation versus observation in patients with fully resected stage IIIA–N2 nonsmall-cell lung cancer and high risk of cerebral metastases after adjuvant chemotherapy

Annals of oncology, 2015-03, Vol.26 (3), p.504-509

2015

Volltextzugriff (PDF)

Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS

Annals of oncology, 2019-02, Vol.30 (2), p.171-210

2019

Volltextzugriff (PDF)

Open access to journal articles in oncology: current situation and citation impact

Annals of oncology, 2017-10, Vol.28 (10), p.2612-2617

2017

Volltextzugriff (PDF)

Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07

Annals of oncology, 2013-03, Vol.24 (3), p.718-725

2013

Volltextzugriff (PDF)

Study on treatment of stage IV solid tumors with mutant neoantigen specific T cells

Annals of oncology, 2018-10, Vol.29, p.viii414-viii415

2018

Volltextzugriff (PDF)

CN67A systematic review and meta-analysis of the distress thermometer for the screening of distress in Chinese patients with cancer

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

Sun, H H

2019

Volltextzugriff (PDF)

402P Updated results from the multicenter phase II, ALTER-C001 trial: Efficacy and safety of anlotinib plus XELOX regimen as first-line treatment followed by maintenance monotherapy of anlotinib for patients with mCRC

Annals of oncology, 2022-09, Vol.33, p.S720-S721

2022

Volltextzugriff (PDF)

424P Update results from ALTER-C-001 study: Efficacy and safety of anlotinib plus XELOX regimen as first-line treatment followed by maintenance monotherapy of anlotinib for patients with mCRC: A single arm, multi-center, phase II clinical trial

Annals of oncology, 2021-09, Vol.32, p.S546-S547

2021

Volltextzugriff (PDF)

440P Maximal tumor area as an independent prognostic factor: Enhancing prognostic assessment in resectable gastric adenocarcinoma

Annals of oncology, 2024-06, Vol.35, p.S177-S177

2024

Volltextzugriff (PDF)

453P Trends, clinicopathological features, surgical treatment patterns and prognoses of early-onset versus late-onset gastric cancer: A retrospective cohort study on 18877 patients managed from 2000 to 2022 in a Chinese cancer center

Annals of oncology, 2024-06, Vol.35, p.S181-S182

2024

Volltextzugriff (PDF)

569P Whole-transcriptome sequencing of transformed small-cell lung cancer from EGFR-mutated lung adenocarcinoma reveals LUAD–like and SCLC–like subsets

Annals of oncology, 2023-11, Vol.34, p.S1693

2023

Volltextzugriff (PDF)

392TiP A prospective phase II study of individualized adjuvant therapy in patients with locally advanced hypopharyngeal cancer after neoadjuvant therapy

Annals of oncology, 2023-11, Vol.34, p.S1619

2023

Volltextzugriff (PDF)

416P Three-dimensional bioprinting model of ovarian cancer for identification of patient-specific therapy response

Annals of oncology, 2023-11, Vol.34, p.S1626

2023

Volltextzugriff (PDF)

P-33 The role of preoperative immune-chemotherapy in locally advanced resectable gastric cancer with microsatellite instability

Annals of oncology, 2023-06, Vol.34, p.S25-S25

2023

Volltextzugriff (PDF)

1765P Second-line targeted therapy patterns and outcomes of advanced gastrointestinal stromal tumor: A prospective, multicentered real-world study

Annals of oncology, 2024-09, Vol.35, p.S1051-S1051

2024

Volltextzugriff (PDF)

394TiP A phase IIIb, single-arm, open-label, multi-center study on durvalumab in combination with gemcitabine-based chemotherapy as first-line treatment for Chinese patients with unresectable biliary tract cancers: TopDouble

Annals of oncology, 2024-06, Vol.35, p.S158-S158

2024

Volltextzugriff (PDF)

A 13-gene signature of DNA repair predicts prognosis in gastric cancer patients

Annals of oncology, 2019-11, Vol.30, p.ix50-ix51

2019

Volltextzugriff (PDF)

1387P Efficacy of first-line treatment options in advanced HER2-altered non-small cell lung cancer: A multi-center retrospective study

Annals of oncology, 2023-10, Vol.34, p.S795-S795

2023

Volltextzugriff (PDF)

2000P Efficacy and safety of thoracic radiotherapy after first-line immunotherapy in extensive stage small cell lung cancer: A multi-center retrospective study

Annals of oncology, 2023-10, Vol.34, p.S1067-S1067

2023

Volltextzugriff (PDF)

276P Dalpiciclib, a novel CDK4/6 inhibitor, combined with pyrotinib for HER2+ advanced breast cancer: Interim results of a phase II trial

Annals of oncology, 2021-09, Vol.32, p.S484-S484

2021

Volltextzugriff (PDF)

45P Durvalumab (D) plus gemcitabine-based (gem-based) chemotherapy as first-line therapy for Chinese patients (pts) with advanced biliary tract cancers (aBTC): A phase IIIb, single arm, open-label, multi-center study (TopDouble)

Annals of oncology, 2024-09, Vol.35, p.S229-S229

2024

Volltextzugriff (PDF)

328P Long-term follow-up of pembrolizumab plus chemotherapy in Chinese patients with metastatic squamous non-small cell lung cancer (NSCLC) from KEYNOTE-407

Annals of oncology, 2022-11, Vol.33, p.S1571

2022

Volltextzugriff (PDF)

P-217 A retrospective, pathologist-based assessment of immunohistochemistry assay for CLDN18.2 expression in digestive system adenocarcinoma

Annals of oncology, 2023-06, Vol.34, p.S93-S93

2023

Volltextzugriff (PDF)

PD-24 A novel molecular subtype for Chinese stage II-III colorectal cancer based on multi-center and large sample size data

Annals of oncology, 2023-06, Vol.34, p.S10-S11

2023

Volltextzugriff (PDF)

1 – 25 von 412

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieAnnals Of Oncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(412)
Mit Volltextzugriff
(412)

Publikationsform

Artikel
(412)

Sprache

Englisch
(412)
Japanisch
(8)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(40)
Oncology
(40)
Science & Technology
(40)
Humans
(38)
Female
(23)
Male
(20)
Middle Aged
(20)
Aged
(18)
Antineoplastic Agents
(17)
Biological And Medical Sciences
(17)
Medical Sciences
(17)
Pharmacology. Drug Treatments
(17)
Adult
(15)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(12)
Tumors
(12)
Aged, 80 And Over
(9)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(9)
Disease-Free Survival
(9)
Lung Neoplasms - Drug Therapy
(9)
Mutation
(9)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Zeitschrift / Serie

Ann Oncol
(1)

Neu hinzugefügt

... seit 7 Tagen
(39)
... seit 90 Tagen
(47)

Menü

Weitere Dienste

Einstellungen

A prognostic scoring system based on clinical features of intrahepatic cholangiocarcinoma: the Fudan score

Randomized phase III trial of prophylactic cranial irradiation versus observation in patients with fully resected stage IIIA–N2 nonsmall-cell lung cancer and high risk of cerebral metastases after adjuvant chemotherapy

Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS

Open access to journal articles in oncology: current situation and citation impact

Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07

Study on treatment of stage IV solid tumors with mutant neoantigen specific T cells

CN67A systematic review and meta-analysis of the distress thermometer for the screening of distress in Chinese patients with cancer

402P Updated results from the multicenter phase II, ALTER-C001 trial: Efficacy and safety of anlotinib plus XELOX regimen as first-line treatment followed by maintenance monotherapy of anlotinib for patients with mCRC

424P Update results from ALTER-C-001 study: Efficacy and safety of anlotinib plus XELOX regimen as first-line treatment followed by maintenance monotherapy of anlotinib for patients with mCRC: A single arm, multi-center, phase II clinical trial

440P Maximal tumor area as an independent prognostic factor: Enhancing prognostic assessment in resectable gastric adenocarcinoma

453P Trends, clinicopathological features, surgical treatment patterns and prognoses of early-onset versus late-onset gastric cancer: A retrospective cohort study on 18877 patients managed from 2000 to 2022 in a Chinese cancer center

569P Whole-transcriptome sequencing of transformed small-cell lung cancer from EGFR-mutated lung adenocarcinoma reveals LUAD–like and SCLC–like subsets

392TiP A prospective phase II study of individualized adjuvant therapy in patients with locally advanced hypopharyngeal cancer after neoadjuvant therapy

416P Three-dimensional bioprinting model of ovarian cancer for identification of patient-specific therapy response

P-33 The role of preoperative immune-chemotherapy in locally advanced resectable gastric cancer with microsatellite instability

1765P Second-line targeted therapy patterns and outcomes of advanced gastrointestinal stromal tumor: A prospective, multicentered real-world study

394TiP A phase IIIb, single-arm, open-label, multi-center study on durvalumab in combination with gemcitabine-based chemotherapy as first-line treatment for Chinese patients with unresectable biliary tract cancers: TopDouble

A 13-gene signature of DNA repair predicts prognosis in gastric cancer patients

1387P Efficacy of first-line treatment options in advanced HER2-altered non-small cell lung cancer: A multi-center retrospective study

2000P Efficacy and safety of thoracic radiotherapy after first-line immunotherapy in extensive stage small cell lung cancer: A multi-center retrospective study

276P Dalpiciclib, a novel CDK4/6 inhibitor, combined with pyrotinib for HER2+ advanced breast cancer: Interim results of a phase II trial

45P Durvalumab (D) plus gemcitabine-based (gem-based) chemotherapy as first-line therapy for Chinese patients (pts) with advanced biliary tract cancers (aBTC): A phase IIIb, single arm, open-label, multi-center study (TopDouble)

328P Long-term follow-up of pembrolizumab plus chemotherapy in Chinese patients with metastatic squamous non-small cell lung cancer (NSCLC) from KEYNOTE-407

P-217 A retrospective, pathologist-based assessment of immunohistochemistry assay for CLDN18.2 expression in digestive system adenocarcinoma

PD-24 A novel molecular subtype for Chinese stage II-III colorectal cancer based on multi-center and large sample size data

Aktive Filter

Suchergebnisse filtern